Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
March 29, 2019 Off

Acerus Pharmaceuticals Corporation Announces Closing of Private Placement

By BusinessWire

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR…

March 29, 2019 Off

Dicerna™ Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)

By BusinessWire

—PHYOX™1 Investigators Reported Potent, Durable Response in Phase 1 Study in Patients with PH1 and PH2 at German Society of…

March 29, 2019 Off

Global Metagenomics Analysis Market Forecast to 2026 – A $1.5+ Billion Opportunity – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Global Metagenomics Analysis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and…

Bicycle Therapeutics to Present Preclinical Data on EphA2 and Nectin-4 Bicycle Toxin Conjugate Programs, as well as a CD137 Immune Oncology Program, at the American Association for Cancer Research Annual Meeting
March 29, 2019 Off

Bicycle Therapeutics to Present Preclinical Data on EphA2 and Nectin-4 Bicycle Toxin Conjugate Programs, as well as a CD137 Immune Oncology Program, at the American Association for Cancer Research Annual Meeting

By BusinessWire

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic…

Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients
March 28, 2019 Off

Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients

By BusinessWire

— Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone — —…

March 28, 2019 Off

Gilead and Galapagos Announce Filgotinib Meets Primary and Key Secondary Endpoints in the Phase 3 FINCH 1 Rheumatoid Arthritis Study

By BusinessWire

— Filgotinib 100 mg and 200 mg Doses Demonstrated Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Prior Inadequate…

March 28, 2019 Off

Gilead and Galapagos Report Updated Safety Information for Filgotinib in Rheumatoid Arthritis (RA)

By BusinessWire

— Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add…

Cytonus Therapeutics Announces Poster Presentation at the 2019 American Association for Cancer Research Annual Meeting
March 28, 2019 Off

Cytonus Therapeutics Announces Poster Presentation at the 2019 American Association for Cancer Research Annual Meeting

By BusinessWire

SAN DIEGO–(BUSINESS WIRE)–Cytonus Therapeutics Inc., a biotechnology company developing new platforms for delivering biologics, announced today that it will be…

March 28, 2019 Off

Quanterix Appoints Amol Chaubal as Chief Financial Officer

By BusinessWire

Amol brings global pharmaceutical and diagnostic industry experience to management team to support rapid company growth LEXINGTON, Mass.–(BUSINESS WIRE)–Quanterix Corporation…

Guided Therapeutics Reports Significant Progress in Eliminating Variable Rate Convertible Loans and Restructuring Capitalization; Announces Reverse Stock Split
March 28, 2019 Off

Guided Therapeutics Reports Significant Progress in Eliminating Variable Rate Convertible Loans and Restructuring Capitalization; Announces Reverse Stock Split

By BusinessWire

NORCROSS, Ga.–(BUSINESS WIRE)—-Guided Therapeutics, Inc. (Pink Sheets: GTHP), the maker of a rapid and painless testing platform based on its…

Posts pagination

Previous 1 … 3,321 3,322 3,323 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine